RFK Jr. Nomination Sparks Market Downturn and Public Health Concerns | Pivot

Sharp declines in vaccine makers, GLP‑1 drug companies, and processed food stocks suggest investors believe his appointment could materially affect regulation, demand, and long‑term industry prospects.

Both hosts emphasize that he is not merely ‘asking questions’ about vaccines but actively promoting debunked theories, potentially reversing hard‑won gains against diseases like measles and polio.

Galloway underscores that vaccines combine scientific breakthroughs, public–private collaboration, and government distribution in ways that have saved more lives than almost any other modern technology.

He describes GLP‑1s as “scaffolding on our instincts,” noting early evidence that users not only eat less junk food but also drink less alcohol and gravitate toward healthier foods, with major implications for healthcare and consumer industries.

They argue the food and medical ecosystems profit from obesity—from processed food giants to hospitals and pharma—while rhetoric about ‘finding your truth’ obscures the reality of diet‑driven disease.